Actuate Therapeutics (ACTU) Q4 2024 earnings summary

Executive summary

• Clinical-stage biopharma focused on GSK-3 inhibition for difficult-to-treat cancers, with lead candidate elraglusib in Phase 2 for metastatic pancreatic ductal adenocarcinoma (mPDAC) and Phase 1/2 for refractory pediatric malignancies, including Ewing sarcoma.

• Completed IPO in August 2024, raising $22 million net proceeds; cash and cash equivalents at year-end were $8.6 million, insufficient for 12 months of operations, raising substantial doubt about going concern.

• No product revenue to date; accumulated deficit of $132.4 million as of December 31, 2024.

Financial highlights

• Net loss for 2024 was $27.3 million, compared to $24.7 million in 2023.

• Research and development expenses decreased to $18.7 million (from $21.7 million), mainly due to lower preclinical, clinical, and manufacturing costs.

• General and administrative expenses increased to $6.5 million (from $3.3 million), driven by higher stock-based compensation, professional fees, and public company costs.

• Cash used in operations was $21.8 million; net cash provided by financing activities was $27.5 million.

Outlook and guidance

• Existing cash is not sufficient to fund operations beyond Q2 2025; additional capital is required to continue development and avoid curtailment or cessation of operations.

• Plans to advance elraglusib into Phase 3 for mPDAC and further studies in Ewing sarcoma and other indications are contingent on securing further funding.